Sunshine Biopharma Signed Exclusive Worldwide License With University Of Arizona For Plpro-based Covid-19 Treatment
Sunshine Biopharma Signed Exclusive Worldwide License With University Of Arizona For Plpro-based Covid-19 Treatment
On February 24, 2023, Sunshine Biopharma, Inc. (the "Company") entered into an Exclusive Patent License Agreement (the "License Agreement") with Arizona Board ofRegents on behalf of the University of Arizona (the "University"). Pursuant to the License Agreement, the University granted to the Company an exclusive worldwide licensefor the University of Arizona and University of Illinois Chicago technology pertaining to inhibitors of the PLpro protease of SARS-CoV-2, the coronavirus that causes COVID-19. The Company agreed to pay the University a royalty of 3% of net sales (as defined in the license agreement) and to pay the University 30% of any revenues received fromsublicensees. The Company also agreed to make certain milestone payments. The License Agreement may be terminated by the University in the event the Company fails toachieve certain milestone
2023年2月24日，Sunshine Biopharma, Inc.（“公司”）代表亚利桑那大学（“大学”）与亚利桑那州董事会签订了独家专利许可协议（“许可协议”）。根据许可协议，该大学向公司授予亚利桑那大学和伊利诺伊大学芝加哥分校技术的全球独家许可，该技术涉及导致 COVID-19 的冠状病毒 SARS-CoV-2 PLPro 蛋白酶抑制剂。公司同意向大学支付净销售额的3％的特许权使用费（定义见许可协议），并向大学支付从分许可证持有人那里获得的任何收入的30％。该公司还同意支付某些里程碑款项。如果公司未能实现某些里程碑，大学可能会终止许可协议
